Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P301 is a synthetic 15-amino acid peptide primarily utilized as a negative control in preclinical research involving Foxp3 (forkhead box P3) inhibition. In studies evaluating the therapeutic efficacy of Foxp3-inhibitory peptides like P60, P301 serves as a non-functional control to demonstrate that the observed immunomodulatory and antitumor effects are specific to the inhibition of the Foxp3 transcription factor. P301 is often derived from the HIV-1 glycoprotein gp120 (amino acids 301-315) or synthesized as a scrambled version of active peptides. While it is used in experimental models of breast cancer and other malignancies to assess the impact of regulatory T cell (Treg) blockade and direct tumor-intrinsic Foxp3 inhibition, P301 itself lacks therapeutic activity and does not inhibit Foxp3 homodimerization or nuclear translocation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on P301.